IOT Innovotech Inc

Innovotech Inc. (TSX VENTURE:IOT), a pioneer in the field of biofilm product
development, today announced that its MBEC Assay(TM) has been approved as an
ASTM International (ASTM) standard. The Assay was validated for testing the
effectiveness of hard surface disinfectants formulated to kill biofilm. The MBEC
Assay(TM) is a biofilm growth device, which allows for the rapid, reproducible
and simultaneous evaluation of multiple test conditions against microorganisms
in their natural, biofilm state.


"Currently, most disinfectants are evaluated using bacteria grown in
suspension," said Dr. Darla M. Goeres, Assistant Research Professor, Center for
Biofilm Engineering (CBE) at Montana State University, and a member of the ASTM
Subcommittee E35 on Pesticides, Antimicrobials, and Alternative Control Agents.
"This method enables companies to determine the efficacy of products against
bacteria in their more natural state, and therefore provides a better approach
for predicting the efficacy of disinfectants under real-use conditions."


"The approval of the MBEC Assay(TM) as an ASTM standard represents a fundamental
shift in how disinfectants will be evaluated on their effectiveness in
protecting against harmful microorganisms," said Ken Boutilier, President and
CEO of Innovotech. "This approval paves the way for a new generation of
disinfectants in the food industry and in hospitals, designed specifically to
address the issue of biofilms, thereby reducing the number of deaths and
sicknesses resulting from foodborne and infection related illnesses."


Biofilms are organized communities of microorganisms that exist in virtually
every natural environment. Biofilms can be up to 1000 times more resistant to
treatment than the same organism in a free-floating state.


A recent report indicated that there are 76 million food related illness a year,
resulting in 325,000 hospitalizations and 5,000 deaths in the US, at a cost to
the economy of $152 billion a year.


In addition to its MBEC Assay(TM), Innovotech sells diagnostic kits that test
bacterial susceptibility against antibiotics under biofilm conditions.


About ASTM International

ASTM International (formerly American Society for Testing and Materials)
provides a global forum for the development and publication of international
voluntary consensus standards for materials, products, systems and services.
Known for their high technical quality and market relevance, ASTM standards are
used in research and development, product testing and quality systems. ASTM
standards are a critical element of the information infrastructure that guides
manufacturing and trade in the global economy. For more information visit
http://www.astm.org/ 


About Innovotech Inc.

Innovotech Inc. is a pioneer in the field of biofilm product development,
focused on providing innovative and practical solutions to medical, agricultural
and industrial problems caused by microbial biofilms. Biofilms are responsible
for a host of diseases both in human health and agriculture due to their
inherent resistance to existing antibiotics and disinfectants. Aside from
Innovotech's products there are currently no antibiotics, disinfectants, or
diagnostics designed specifically for biofilm-forming organisms. 


Innovotech currently has two commercial products, the MBEC Assay(TM) and bioFILM
PA(TM), and one product, Agress(R), in advanced stages of development. The MBEC
Assay(TM) is a high throughput biofilm growth device. bioFILM PA(TM) is the
first diagnostic kit to assist physicians in the selection of the most effective
combination antibiotic treatment of patients with biofilm-based chronic lung
infections and Agress(R) is a unique, environmentally friendly seed treatment
and plant spray designed to protect crops against both bacterial and fungal
infections.


Connect with us:

Website: www.innovotech.ca

Blog: www.cf-test.ca

Twitter:www.twitter.com/innovotech

Facebook:www.facebook.com/innovotech

This document may contain forward-looking statements that are predictive in
nature and subject to risks and uncertainties that cannot be predicted or
quantified; consequently, actual results may differ materially from past results
and those expressed or implied by any forward-looking statements. Factors that
could cause or contribute to such risks or uncertainties include, but are not
limited to: the regulatory environment including the difficulty of predicting
regulatory outcomes; changes in the value of the Canadian dollar; the Company's
reliance on a small number of customers including government organizations;
fluctuations in operating results; government policies or actions; progress and
cost of clinical trials; reliance on key strategic relationships; uncertainty
related to intellectual property protection and potential costs associated with
its defense; the Company's exposure to lawsuits and other matters beyond the
control of management. Should known or unknown risks or uncertainties
materialize, or should management's assumptions prove inaccurate, actual results
could vary materially from those anticipated. The Company undertakes no
obligation to publicly make or update any forward-looking statements, except as
required by applicable law.

Innovotech (TSXV:IOT)
Historical Stock Chart
From Jun 2024 to Jul 2024

Innovotech (TSXV:IOT)
Historical Stock Chart
From Jul 2023 to Jul 2024